AXIM' Partner Empowered Files EUA With FDA For Use Of Rapid COVID-19 Neutralizing Antibody Test

AXIM Biotechnologies Inc. (AXIM.OB) said that its manufacturing partner, Empowered Diagnostics, has filed an Emergency Use Authorization or EUA application with the US Food and Drug Administration for the approval to use ImmunoPass, the company's rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies, to detect COVID-19 neutralizing antibodies in whole blood at point-of-care locations.

AXIM said earlier this month that it completed clinical trials, identifying that operators found ImmunoPass easy to use and that they encountered no issues in using the company's test to measure participants' levels of COVID-19 neutralizing antibodies.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Spirit Airlines has canceled or delayed hundreds of flights following significant operational challenges. The low-cost carrier blamed weather, staffing shortages, and system outages for the issues that caused thousands of passengers stranded in the airports. General Motors Co. (GM) said its second-quarter results were better than originally expected due to strong pricing and demand, record GM Financial results and improved near-term production from the pull forward of semiconductors from the third quarter. Based on first-half performance and expectations... PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately...
Follow RTT